These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 34244013)

  • 1. Associations of retention on buprenorphine for opioid use disorder with patient characteristics and models of care in the primary care setting.
    Bailey SR; Lucas JA; Angier H; Cantone RE; Fleishman J; Garvey B; Cohen DJ; Rdesinski RE; Gordon L
    J Subst Abuse Treat; 2021 Dec; 131():108548. PubMed ID: 34244013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence and treatment of opioid use disorders among primary care patients in six health systems.
    Lapham G; Boudreau DM; Johnson EA; Bobb JF; Matthews AG; McCormack J; Liu D; Samet JH; Saxon AJ; Campbell CI; Glass JE; Rossom RC; Murphy MT; Binswanger IA; Yarborough BJH; Bradley KA;
    Drug Alcohol Depend; 2020 Feb; 207():107732. PubMed ID: 31835068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psychosocial and behavioral therapy in conjunction with medication for opioid use disorder: Patterns, predictors, and association with buprenorphine treatment outcomes.
    Samples H; Williams AR; Crystal S; Olfson M
    J Subst Abuse Treat; 2022 Aug; 139():108774. PubMed ID: 35337716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integration of Buprenorphine Treatment with Primary Care: Comparative Effectiveness on Retention, Utilization, and Cost.
    Hsu YJ; Marsteller JA; Kachur SG; Fingerhood MI
    Popul Health Manag; 2019 Aug; 22(4):292-299. PubMed ID: 30543495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Three-year Retention Rates With Office-based Treatment of Buprenorphine for Opioid Use Disorder in a Private Family Medicine Practice.
    Cope K; DeMicco J; Salib J; Michael M; Yakoub P; Daoud K; Cope R
    J Addict Med; 2022 Nov-Dec 01; 16(6):716-721. PubMed ID: 35913992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient Barriers and Facilitators to Medications for Opioid Use Disorder in Primary Care.
    Tofighi B; Williams AR; Chemi C; Suhail-Sindhu S; Dickson V; Lee JD
    Subst Use Misuse; 2019; 54(14):2409-2419. PubMed ID: 31429351
    [No Abstract]   [Full Text] [Related]  

  • 7. PRimary Care Opioid Use Disorders treatment (PROUD) trial protocol: a pragmatic, cluster-randomized implementation trial in primary care for opioid use disorder treatment.
    Campbell CI; Saxon AJ; Boudreau DM; Wartko PD; Bobb JF; Lee AK; Matthews AG; McCormack J; Liu DS; Addis M; Altschuler A; Samet JH; LaBelle CT; Arnsten J; Caldeiro RM; Borst DT; Stotts AL; Braciszewski JM; Szapocznik J; Bart G; Schwartz RP; McNeely J; Liebschutz JM; Tsui JI; Merrill JO; Glass JE; Lapham GT; Murphy SM; Weinstein ZM; Yarborough BJH; Bradley KA
    Addict Sci Clin Pract; 2021 Jan; 16(1):9. PubMed ID: 33517894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nine-year substance use treatment outcomes with buprenorphine for opioid use disorder in a federally qualified health center.
    Haddad M; Coman E; Bifulco L
    Drug Alcohol Depend; 2024 Apr; 257():111252. PubMed ID: 38484404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term retention in Office Based Opioid Treatment with buprenorphine.
    Weinstein ZM; Kim HW; Cheng DM; Quinn E; Hui D; Labelle CT; Drainoni ML; Bachman SS; Samet JH
    J Subst Abuse Treat; 2017 Mar; 74():65-70. PubMed ID: 28132702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Buprenorphine Receipt and Retention for Opioid Use Disorder Following an Initiative to Increase Access in Primary Care.
    Hawkins EJ; Malte CA; Hagedorn HJ; Gordon AJ; Williams EC; Trim RS; Blanchard BE; Lott A; Danner AN; Saxon AJ
    J Addict Med; 2024 May-Jun 01; 18(3):240-247. PubMed ID: 38329814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Community-Based Medication-First program for opioid use disorder: a hybrid implementation study protocol of a rapid access to buprenorphine program in Washington State.
    Banta-Green CJ; Owens MD; Williams JR; Sears JM; Floyd AS; Williams-Gilbert W; Kingston S
    Addict Sci Clin Pract; 2022 Jul; 17(1):34. PubMed ID: 35799210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Receipt of medications for opioid use disorder among youth engaged in primary care: data from 6 health systems.
    Bagley SM; Chavez L; Braciszewski JM; Akolsile M; Boudreau DM; Lapham G; Campbell CI; Bart G; Yarborough BJH; Samet JH; Saxon AJ; Rossom RC; Binswanger IA; Murphy MT; Glass JE; Bradley KA;
    Addict Sci Clin Pract; 2021 Jul; 16(1):46. PubMed ID: 34233750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Buprenorphine Medication for Opioid Use Disorder: A Study of Factors Associated With Postpartum Treatment Retention.
    Ray-Griffith S; Tharp E; Coker JL; Catlin D; Knight B; Stowe ZN
    Am J Addict; 2021 Jan; 30(1):43-48. PubMed ID: 32673447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polysubstance use and association with opioid use disorder treatment in the US Veterans Health Administration.
    Lin LA; Bohnert ASB; Blow FC; Gordon AJ; Ignacio RV; Kim HM; Ilgen MA
    Addiction; 2021 Jan; 116(1):96-104. PubMed ID: 32428386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trauma treatment for veterans in buprenorphine maintenance treatment for opioid use disorder.
    Meshberg-Cohen S; Black AC; DeViva JC; Petrakis IL; Rosen MI
    Addict Behav; 2019 Feb; 89():29-34. PubMed ID: 30243036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sociodemographic and prescribing characteristics that impact long-term retention in buprenorphine treatment for opioid use disorder among a statewide population.
    Hallowell BD; Chambers LC; Samuels EA; Bratberg J; McDonald J; Nitenson A; Onyejekwe C; Beaudoin FL
    Drug Alcohol Depend; 2022 Dec; 241():109680. PubMed ID: 36335834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polysubstance Use in Adults With Opioid Use Disorder Receiving Buprenorphine Maintenance.
    Elarabi HF; Radwan DN; Adem A; Marsden J; Lee AJ
    J Addict Med; 2023 Jan-Feb 01; 17(1):74-78. PubMed ID: 35793664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short communication: Relationship between social determinants and opioid use disorder treatment outcomes by gender.
    Parlier-Ahmad AB; Radic M; Svikis DS; Martin CE
    Drug Alcohol Depend; 2022 Mar; 232():109337. PubMed ID: 35123364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Documented opioid use disorder and its treatment in primary care patients across six U.S. health systems.
    Boudreau DM; Lapham G; Johnson EA; Bobb JF; Matthews AG; McCormack J; Liu D; Campbell CI; Rossom RC; Binswanger IA; Yarborough BJ; Arnsten JH; Cunningham CO; Glass JE; Murphy MT; Zare M; Hechter RC; Ahmedani B; Braciszewski JM; Horigian VE; Szapocznik J; Samet JH; Saxon AJ; Schwartz RP; Bradley KA
    J Subst Abuse Treat; 2020 Mar; 112S():41-48. PubMed ID: 32220410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Tramadol Extended-Release for Opioid Withdrawal: A Randomized Clinical Trial.
    Dunn KE; Tompkins DA; Bigelow GE; Strain EC
    JAMA Psychiatry; 2017 Sep; 74(9):885-893. PubMed ID: 28700791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.